Roche's eyesight drug may curb diabetes-related macular edema

06/28/2011 | Bloomberg

Using Roche Holding's Lucentis drug helped improve the vision and curb blood vessel abnormalities in patients with diabetes-related macular edema, experts reported at the annual meeting of the American Diabetes Association. Lucentis-treated patients were more likely to have 20/40 vision compared with those who took a placebo, experts said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY